EMD-48524

Single-particle
3.9 Å
EMD-48524
3D View Gallery
Deposition: 03/01/2025
Map released: 12/02/2025
Last modified: 12/02/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-48524

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-9mqh summary report (pdf.gz) Map-9mqh FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

Inactive Mu-Opioid Receptor with Nb6M, NabFab, and isoquinuclidine compound #33

EMD-48524

Single-particle
3.9 Å
EMD-48524
3D View Gallery
Deposition: 03/01/2025
Map released: 12/02/2025
Last modified: 12/02/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens
Sample: Human Mu-Opioid Receptor
Fitted models: 9mqh

Deposition Authors: Kim JY , Vigneron SF , Billesbolle C, Manglik A , Shoichet BK
Docking 14 million virtual isoquinuclidines against the mu and kappa opioid receptors reveals dual antagonists-inverse agonists with reduced withdrawal effects.
Vigneron SF , Ohno S , Braz J, Kim JY , Kweon OS , Webb C , Billesbolle C, Bhardwaj K , Irwin J, Manglik A , Basbaum AI , Ellman JA , Shoichet BK
(2025) bioRxiv
PUBMED: 39868130
DOI: doi:10.1101/2025.01.09.632033
ISSN: 2692-8205